Schizophrenia

This phase 3 trial is testing the long-term safety of an oral drug called HS-10380 in Chinese adults with schizophrenia. Over about a year, 500 participants will take the medication daily, with doses adjusted to an optimal level. The study tracks side effects, serious adverse eve…

This phase 2 trial tests whether adding a combination of deferiprone (an iron-chelating drug) and N-acetylcysteine (an antioxidant) to standard antipsychotic treatment can reduce the negative symptoms of schizophrenia, such as apathy, lack of motivation, and social withdrawal. Ab…

This pilot study will test whether deep brain stimulation (DBS) can help people with schizophrenia who still hear voices and have delusions despite trying multiple medications. Fifteen adults will have electrodes placed in a brain region linked to schizophrenia symptoms. The goal…

This trial tests a medical device that has not yet been approved by the U.S. FDA. The goal is to see if it can help control a specific disease. Participants will use the device as directed, and researchers will monitor its effects on symptoms and disease progression.

This pilot study tests whether combining a gentle brain stimulation technique called tDCS with aerobic exercise can improve cognitive functions like memory and attention in people with schizophrenia. Participants will be randomly assigned to receive either the combined treatment …

This trial is testing a new extended-release injection of brexpiprazole, a medication already used for schizophrenia, to see how it behaves in the body and whether it is safe and tolerable. About 16 adults with schizophrenia will receive a single dose of either 45 mg or 100 mg un…

This trial compares a new long-acting injectable form of the schizophrenia drug cariprazine (called B2227) with the standard oral version, Vraylar. Researchers want to see how the body absorbs and processes each version, and whether the injectable is safe and tolerable. The study…

This early-stage trial is testing a long-acting injectable form of the drug cariprazine, called AX251, in 48 adults with stable schizophrenia. The study aims to see how the drug moves through the body and whether it is safe when given as a single shot at different doses. If resul…

This study tests an experimental drug called VV119 in adults with acute schizophrenia. Participants receive one of three doses of VV119, a placebo, or an active comparator (aripiprazole) for six weeks. The goal is to see if VV119 reduces symptoms like hallucinations and delusions…

This trial investigates whether a gamified eye-movement training program can improve cognitive function in people across different stages of schizophrenia, including those at clinical high risk. Participants will be randomly assigned to either eye-movement training or a finger-co…

This study tests whether a digital platform called mindLAMP can help community health workers in India deliver better care for people with schizophrenia. About 240 adults with schizophrenia and at least one physical health risk (like diabetes or high blood pressure) will take par…

This phase 3 trial tests whether KarXT (a combination of xanomeline and trospium chloride) can prevent relapse in people with schizophrenia. Participants who have had a recent hospitalization for schizophrenia and still have symptoms will receive KarXT or a placebo. The study mea…

This study tests a smartphone-based digital training program designed to improve working memory in people with schizophrenia or related disorders. Participants use the app to practice cognitive exercises, and researchers measure changes in memory and mental health. The goal is to…

This study tests a program that combines executive function training (like planning and problem-solving) with cognitive behavioral social skills training for adults aged 60 and older who have schizophrenia or schizoaffective disorder. Participants attend 42 sessions that teach pr…

This study compares dapagliflozin and metformin for managing weight gain caused by antipsychotic medications. About 110 adults aged 16 and older will take one of the drugs plus lifestyle advice for 26 weeks. The goal is to see which drug works better and is safer for weight contr…

This study tests a brain implant called deep brain stimulation (DBS) to help six adults with severe aggression that hasn't improved with medication or other therapies. Participants have either autism or schizophrenia and live in locked psychiatric units. The implant targets a bra…

This early study tests a new drug called SIPI6398 in 9 people (healthy volunteers and schizophrenia patients). Researchers use brain scans to see how much of the drug reaches brain receptors linked to schizophrenia. The goal is to find the right dose and check safety, not yet to …

This study tests a drug called mirikizumab, which is already approved for other conditions, in people with schizophrenia who have a specific immune marker (AGA IgG antibodies). The goal is to see if it can improve negative symptoms like lack of motivation and pleasure, as well as…

This study tests whether carefully reducing antipsychotic medication in stable schizophrenia patients can improve their daily functioning compared to staying on the same dose. Researchers will group 288 adults aged 18–60 by their specific psychosis type and randomly assign them t…

This study tests whether a personalized program of exercise, diet, sleep support, social activities, and a weight-loss drug (semaglutide) can improve mental functioning in 140 adults with depression, bipolar disorder, or schizophrenia. Participants are randomly assigned to the pe…

This study tests whether tracking smartphone activity and offering extra support from peer specialists can help veterans with serious mental illness avoid emergency room visits and hospital stays. About 400 veterans who are at high risk will take part. The goal is to catch early …

This study compares a new injectable form of aripiprazole (SYH9096) to the approved drug Abilify Maintena® in 116 adults with stable schizophrenia. Participants receive five injections of each version, one month apart, to see if the new version reaches similar drug levels in the …

This study looks at whether an online education and support program can help people with schizophrenia or bipolar disorder stick to their medication plans. Researchers will compare digital questionnaires with pharmacy records to measure adherence. About 1,640 adults in Spain will…

This study looks at whether extra education from a pharmacist can help people aged 18-60 who are starting a new antipsychotic medication for conditions like schizophrenia or bipolar disorder. The goal is to see if this support reduces weight gain and other metabolic side effects.…

This study tests whether deep brain stimulation (DBS) — a device that sends electrical pulses to specific brain areas — can help people with schizophrenia that hasn't improved with medication. Ten adults aged 18-55 will have electrodes implanted in two brain regions and receive d…

This study tests whether adding cannabidiol (CBD) to the standard drug clozapine helps people with treatment-resistant psychosis. 250 participants will receive either CBD or a placebo for 12 weeks. Researchers will measure symptom changes and check safety.

This study tests a group psychoeducation program for people with schizophrenia to help them manage relapse and improve functional recovery. Sixty participants will be split into two groups: one receives the program (four 60-minute sessions) and the other does not. Researchers wil…

This study tests whether switching from daily oral antipsychotics to a monthly injection of paliperidone palmitate helps people with schizophrenia control symptoms and improve social function. Researchers will enroll 120 adults aged 18-65 who are stable on oral meds. Participants…

This small pilot study tests whether bromocriptine, a drug used for Parkinson's, can safely improve blood sugar problems in people with schizophrenia who have prediabetes from antipsychotic medications. Fifteen adults will take bromocriptine for 6 weeks, with researchers monitori…

This study will test the safety and effectiveness of paliperidone extended-release tablets in 505 adults with schizophrenia in Bangladesh. Participants will take the medication once daily for 12 weeks, with doses adjusted as needed. Researchers will measure changes in symptoms us…

This study tests whether a non-invasive brain ultrasound, combined with machine learning, can help distinguish people with schizophrenia from healthy individuals. Researchers will scan 200 adults (100 with schizophrenia, 100 without) and measure specific brain features. The goal …

This study will test whether measuring a specific abnormal protein (alpha-synuclein) in spinal fluid can reliably distinguish dementia with Lewy bodies (DLB) from Alzheimer's disease. Researchers will collect samples and perform cognitive tests on 286 older adults with suspected …

This trial investigates whether a traditional Chinese medicine formula, Xingqi Daozhi Decoction, can relieve constipation that often occurs as a side effect of antipsychotic medications in people with schizophrenia. The study will enroll 46 adults with schizophrenia who have deve…

This study compares two types of brain stimulation—accelerated theta burst and high-frequency TMS—against a sham (fake) treatment to see if they can improve cognitive problems like memory and attention in people with treatment-resistant schizophrenia. Ninety adults on clozapine w…

This trial tests whether Snoezelen therapy—a calming, multisensory experience using lights, sounds, and textures—can improve health in adults with schizophrenia (including those needing institutional care) and women with alcohol dependence. Participants will attend 30-minute sess…

This study tests a narrative therapy program designed to help people with schizophrenia reduce self-stigma. Twenty-four participants from halfway houses in northern Taiwan will attend four group and four individual sessions over eight weeks, using storytelling and workbook exerci…

This study will test a mobile app designed to help people with schizophrenia or those at high risk for psychosis recognize and change biased thinking patterns. One hundred participants will use the app and report on their mood and negative symptoms. The goal is to see if this sim…

This study tests whether a non-invasive brain stimulation technique called temporal interference stimulation can reduce negative symptoms (like lack of emotion or motivation) and cognitive problems in people with schizophrenia. 62 participants will receive either real or sham sti…

This study tests a 12-week online program designed to improve mood and motivation in people with schizophrenia or early psychosis. Participants complete 20-30 minute weekly sessions. Researchers will measure changes in symptoms and goal-directed behavior before and after the prog…

This study tests whether a mobile app that trains specific brain waves can improve working memory in adults with schizophrenia or schizoaffective disorder. Thirty participants will use the app at home twice a week for 12 weeks. Half get real neurofeedback, half get a placebo vers…

This study tests whether 8 weekly group sessions of Acceptance and Commitment Therapy (ACT), led by a nurse, can help people with schizophrenia improve social thinking, emotion control, and mental flexibility. 64 participants will be split into two groups: one gets ACT plus usual…

This study tests whether an 8-session training program based on Acceptance and Commitment Therapy (ACT) can help caregivers of schizophrenia patients feel less burdened, express emotions more healthily, and become more psychologically flexible. About 60 caregivers will be randoml…

This study tests whether a daily supplement of sulforaphane, a compound found in broccoli sprouts, can improve negative symptoms (like lack of motivation) and thinking problems in people with schizophrenia. Sixty participants aged 12 to 45 who are stable on antipsychotic medicati…

This study tests whether gentle ultrasound waves aimed at the brain can help with memory and thinking problems in people with schizophrenia. 140 adults with stable schizophrenia will receive either real or fake ultrasound sessions over 20 days. Researchers will check if memory an…

This study tests a personalized brain stimulation technique called HD-tACS to help people with schizophrenia better combine information from their senses. The treatment is tailored to each patient's brain activity and targets areas involved in sensory binding. The trial will incl…

This study tests a new therapy that combines face-to-face sessions with virtual reality (VR) to help people with psychosis manage their emotions. Participants will practice emotion regulation skills in realistic VR scenarios with live coaching from a therapist. Fifteen people wit…

This study tests whether a 45-minute session of viewing visual illusions with a partner can improve social cognition in people with psychotic disorders. Social cognition is the ability to understand what others think or feel. Sixty participants will be guided through illusion box…

This study tests a smartphone app called NST-SPARK that uses augmented reality games to help people with schizophrenia who struggle with low motivation, lack of pleasure, and social withdrawal. About 30 adults with these symptoms will use the app for 12 weeks. The goal is to see …

This study tests whether a non-invasive brain training technique called gamma EEG neurofeedback can improve working memory in adults with schizophrenia or schizoaffective disorder. About 104 participants will be randomly assigned to receive either real neurofeedback (learning to …

This study tests whether a new medicine, Xanomeline/Trospium (also called KarXT), can improve thinking and memory in adults with schizophrenia. Unlike standard antipsychotics, this drug targets a different brain system and may help with cognitive symptoms. Researchers will follow…

This study tests a group program called Veteran Voices and Visions (VVV) for veterans with psychosis who hear voices. The program, led by a peer specialist and a clinician, aims to reduce distress and help veterans feel a sense of belonging. 160 veterans will be randomly assigned…

This study tests a shared decision-making tool for antipsychotic medications in 120 young adults (ages 18-30) with early psychosis. The goal is to see if the tool helps patients feel more involved in their care and more likely to stick with treatment. Participants will use the de…

This early-phase pilot study will test whether a nasal spray containing exosomes from human dental stem cells is safe and feasible for people with treatment-resistant schizophrenia who have persistent negative symptoms like social withdrawal and lack of emotion. Fifteen long-term…

This study will test whether an 8-week hatha yoga program is practical and helpful for adults hospitalized with schizophrenia. The goal is to see if yoga can improve mindfulness and how patients recall memories. Thirty-six stable patients will participate in group yoga sessions l…

This study tests whether aerobic exercise, alone or with a gentle brain stimulation technique called tDCS, can improve thinking and memory in people with treatment-resistant schizophrenia. About 160 participants will be assigned to exercise, tDCS plus exercise, or a control group…

This study tests an experimental drug called LY03020 in 160 adults with schizophrenia who are currently having severe symptoms (acute psychosis). Half will get the drug and half a placebo, and neither the patients nor the doctors will know who gets what. The main goal is to see i…

This study tests whether a supplement called pyrroloquinoline quinone (PQQ) can help reduce negative symptoms (like lack of motivation) and improve thinking skills in people with chronic schizophrenia. About 70 adults will receive either PQQ or a placebo for 8 weeks, and research…

This study tests whether a type of talk therapy called narrative exposure therapy (NET) is practical and helpful for people with psychosis who have experienced trauma. One participant will receive NET sessions and complete questionnaires about their symptoms and experiences. The …

This trial tests whether cabergoline, a drug that lowers the hormone prolactin, is safe for people with schizophrenia who have high prolactin levels due to antipsychotic medication. About 146 adults will receive either cabergoline or a placebo for 12 weeks, and researchers will c…

This early study tests whether a device that delivers synchronized 40 Hz light and sound (called GENUS) is safe and feasible for people with schizophrenia. The goal is to see if this at-home stimulation can improve brain rhythms, thinking, and symptoms that current medications do…

This study aims to see if peer support can help pregnant and postpartum veterans who have serious mental illness. Researchers will develop a program where trained peer specialists offer support, then test it with 24 veterans to see if it is helpful and practical. The goal is to i…

This study tests whether adding cannabidiol (CBD) to standard antipsychotic medication can improve symptoms in people experiencing their first episode of psychosis who haven't responded well to initial treatment. About 250 participants aged 16-40 will receive either CBD or a plac…

This study tests a 15-session group therapy program for people with schizophrenia who still hear voices despite medication. The program combines several proven strategies to help reduce how often the voices occur and how much distress they cause. Researchers will compare the ther…

This study tests whether prucalopride, a drug used for gut issues, can improve thinking and memory in people with schizophrenia. About 34 adults will take the drug for 4 weeks while staying on their usual medications. Researchers will measure changes in memory, attention, and pro…

This study tests whether a device that sends magnetic pulses to nerves (peripheral magnetic stimulation) can reduce symptoms and improve daily function in older adults with schizophrenia. Forty participants aged 60 and older will be split into groups receiving either active or sh…

This study will test if art therapy sessions can lower anxiety and disease severity in 48 adults hospitalized in a psychiatry ward. Participants will be randomly assigned to receive art therapy plus standard care or standard care alone. The goal is to see if creative expression c…

This study compares standard metacognitive training (MCT) with a personalized version (P-MCT) for people with schizophrenia spectrum disorder. The goal is to see which approach better improves daily functioning and reduces symptoms. Fifty-one adults with stable psychosis will tak…

This study tests whether an AI-powered app that guides chewing exercises can improve oral hygiene, chewing, and swallowing in people with schizophrenia. 100 participants from two hospitals will be randomly assigned to use the app before meals or receive standard care. The goal is…

This study is looking for biological markers in the body that might predict how well people with treatment-resistant psychiatric disorders—like schizophrenia, depression, bipolar disorder, OCD, and catatonia—respond to new treatments. Researchers will collect blood, stool, cerebr…

This study uses PET scans to see how two antipsychotic medications, brexpiprazole and cariprazine, bind to dopamine-3 receptors in the brains of people with schizophrenia. Forty participants take one of the drugs for 15 days and get brain scans before, after one day, and after 15…

This study follows 2,000 adults with severe mental illness (such as schizophrenia, bipolar disorder, or severe depression) who are admitted to intensive care units (ICUs) in France. Researchers track their survival and other outcomes for up to 12 months to identify factors that p…

This study will examine whether certain RNA molecules in the blood are different in people with psychiatric disorders like schizophrenia, depression, bipolar disorder, OCD, and panic disorder. Researchers will compare these molecules in patients who are not currently on medicatio…

This study will analyze the complete DNA of 1,500 people in Manitoba—some with schizophrenia and some without—to find genetic differences linked to the illness. Researchers will also look at how genes affect medication response and side effects. The goal is to better understand s…

This study will test a new mobile mental health app designed to help people with schizophrenia or schizoaffective disorder stick to their medication routine. Researchers will enroll 50 adults who are in remission and see if using the app is practical and well-liked. The goal is t…

This early-stage study is testing a new drug called KR23248 in 66 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo. This study does not aim to treat any disease but to…

This study follows 600 offenders with both mental illness and substance abuse in Italy and California over three years. Researchers will compare community-based care in Italy with high-security hospitals in the US to see which model leads to better outcomes, like reduced violence…

This study tests a group program to help veterans with serious mental illness feel more comfortable and confident working with their doctors and therapists. About 119 veterans from three VA centers will take part. The goal is to see if the program improves teamwork between vetera…

This study will test whether educational sessions can improve health literacy and attitudes toward medication in 34 adults hospitalized with schizophrenia or related disorders. Participants will receive pamphlets and watch videos about their condition, then complete questionnaire…

This study will follow 120 people with schizophrenia who use cannabis, using mobile phone surveys and thinking tasks to track symptoms in real time. The goal is to understand how cannabis may both worsen positive symptoms (like hallucinations) and reduce negative symptoms (like l…

This early-stage trial will give 8 healthy men a single dose of a radioactive-labeled experimental drug called SEP-380135, which is being developed for schizophrenia. The goal is to track how the drug is absorbed, broken down, and eliminated from the body. This study does not tes…

This research looks at how brain networks relate to thinking and memory problems in people with schizophrenia, bipolar disorder, or major depression. The goal is to use brain imaging to better assess cognitive issues, improve diagnosis, and predict how well treatments might work.…

This study tests whether a short virtual reality experience can reduce stigma toward people with schizophrenia among healthcare workers and students. Participants will watch two VR videos that simulate hallucinations and paranoid thoughts, then researchers measure changes in atti…

This study looks at whether teaching people in the hospital about their psychiatric medications helps them stick to their treatment and handle side effects. Researchers will work with 64 adults who have serious mental illnesses like schizophrenia or bipolar disorder. The goal is …

This study looks at how people with a first episode of psychosis tell their life stories and whether that relates to their well-being and recovery. Researchers will compare 96 participants—those with early psychosis, those with chronic psychosis, and healthy controls—using questi…

This study investigates how insulin delivered through the nose changes dopamine signaling and energy use in the brains of people with first-episode psychosis. Researchers will compare brain scans and chemical levels in 46 participants (patients and healthy volunteers) after recei…

This study will follow 200 adults in Egypt who have psychosis to compare two conditions: schizophrenia and psychosis caused by methamphetamine use. Researchers will assess symptoms, treatment response, and recovery over three months. The goal is to improve diagnosis and understan…

This study is developing and testing a program called Cannabis Conversation Skills for Families (CCSF) that teaches family members communication skills to encourage their young adult loved one with first episode psychosis to reduce cannabis use. The program includes education abo…